

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptau153cxa

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	Jul 12	BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS	4	Jul 30	BEILSTEIN on STN workshop to be held August 24 in conjunction with the 228th ACS National Meeting
NEWS	5	AUG 02	IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS	6	AUG 02	Caplus and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS	7	AUG 02	The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS	8	AUG 04	Pricing for the Save Answers for SciFinder Wizard within STN Express with Discover! will change September 1, 2004
NEWS	9	AUG 27	BIOCOMMERCE: Changes and enhancements to content coverage
NEWS	10	AUG 27	BIOTECHABS/BIOTECHDS: Two new display fields added for legal status data from INPADOC
NEWS	11	SEP 01	INPADOC: New family current-awareness alert (SDI) available
NEWS	12	SEP 01	New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS	13	SEP 01	New display format, HITSTR, available in WPIDS/WPINDEX/WPIX
NEWS	14	SEP 14	STN Patent Forum to be held October 13, 2004, in Iselin, NJ
NEWS EXPRESS			JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:59:25 ON 25 SEP 2004

=> file caplus uspatful japio europatful medline biosis embase scisearch		
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'CAPLUS' ENTERED AT 15:59:46 ON 25 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 15:59:46 ON 25 SEP 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 15:59:46 ON 25 SEP 2004
COPYRIGHT (C) 2004 Japanese Patent Office (JPO)- JAPIO

FILE 'EUROPATFULL' ENTERED AT 15:59:46 ON 25 SEP 2004
COPYRIGHT (c) 2004 WILA Verlag Muenchen (WILA)

FILE 'MEDLINE' ENTERED AT 15:59:46 ON 25 SEP 2004

FILE 'BIOSIS' ENTERED AT 15:59:46 ON 25 SEP 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'EMBASE' ENTERED AT 15:59:46 ON 25 SEP 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 15:59:46 ON 25 SEP 2004
Copyright (c) 2004 The Thomson Corporation.

=> s (acryl? or vinyl?) and polymer?

4 FILES SEARCHED...

L1 976875 (ACRYL? OR VINYL?) AND POLYMER?

=> s l1 and (HTB or trifusal)

L2 878 L1 AND (HTB OR TRIFUSAL)

=> s l2 and hydroly?

L3 376 L2 AND HYDROLY?

=> s l3 and covalent

L4 202 L3 AND COVALENT

=> s l3 and copolymer?

<-----User Break----->

L5 129 L3 AND COPOLYMER?

=> s l4 and copolymer?

L6 99 L4 AND COPOLYMER?

=> s l6 and (carboxylic ester)

L7 1 L6 AND (CARBOXYLIC ESTER)

=> d l7 1 ibib abs

'ABS' IS NOT A VALID FORMAT FOR FILE 'EUROPATFULL'

The following are valid formats:

MAX ----- AN, ED, UP, EW, FS, TI, TIDE, TIFR, IN, PA, PAN, AG, AGN,
OS, SO, DT, LA, DS, PIT, PI, OD, AI, PRAI, RLI, NTE, REP,
REN, IC (ICM, ICS), ICA, ICI, CM, FA, GIS, PGC, CLMN, AB,
ABDE, ABFR, DETD, DETDDE, DETDFR, CLMDE, CLMFR

MAXG ----- MAX plus GI

MAX.OS ----- MAX, OS only

MAXG.OS ----- MAX.OS plus GI

MAX.PS ----- MAX, PS only

IMAX ----- MAX, indented with text labels
 IMAX.OS ---- MAX, indented with text labels, OS only
 IMAX.PS ---- MAX, indented with text labels, PS only

ALL ----- AN, ED, UP, EW, FS, TI, IN, PA, PAN, AG, AGN, OS, SO, DT,
 LA, DS, PIT, PI, OD, AI, PRAI, RLI, NTE, REP, REN, IC (ICM,
 ICS), ICA, ICI, CM, FA, GIS, PGC, CLMN, AB*, DETD*, CLM*
 (* German or French text if English text is not available)

ALLG ----- ALL plus GI
 ALL.OS ---- ALL, OS only
 ALLG.OS ---- ALL.OS plus GI
 ALL.PS ---- ALL, PS only
 IALL ----- ALL, indented with text labels
 IALLG ----- IALL plus GI
 IALL.OS ---- ALL, indented with text labels, OS only
 IALLG.OS --- IALL.OS plus GI
 IALL.PS ---- ALL, indented with text labels, PS only

ALLDE ----- AN, ED, UP, EW, FS, TIDE, IN, PA, PAN, AG, AGN, OS, SO, DT,
 LA, DS, PIT, PI, OD, AI, PRAI, RLI, NTE, REP, REN, IC (ICM,
 ICS), ICA, ICI, CM, FA, GIS, PGC, CLMN, ABDE*, DETDDE*, CLMDE*
 (* English or French text if German text is not available)

ALLGDE ----- ALLDE plus GI
 ALLDE.OS --- ALLDE, OS only
 ALLGDE.OS -- ALLDE.OS plus GI
 ALLDE.PS --- ALLDE, PS only

ALLFR ----- AN, ED, UP, EW, FS, TIFR, IN, PA, PAN, AG, AGN, OS, SO, DT,
 LA, DS, PIT, PI, OD, AI, PRAI, RLI, NTE, REP, REN, IC (ICM,
 ICS), ICA, ICI, CM, FA, GIS, PGC, CLMN, ABFR*, DETDFR*, CLMFR*
 (* English or German text if French text is not available)

ALLGFR ----- ALLFR plus GI
 ALLFR.OS --- ALLFR, OS only
 ALLGFR.OS -- ALLFR.OS plus GI
 ALLFR.PS --- ALLFR, PS only

BRIEF ----- AN, ED, UP, EW, FS, TI, IN, PA, PAN, AG, AGN, OS, SO, DT,
 LA, DS, PIT, PI, OD, AI, PRAI, RLI, NTE, REP, REN, IC (ICM,
 ICS), ICA, ICI, CM, FA, GIS, PGC, CLMN, AB*, MCLM*
 (* German or French text if English text is not available)

BRIEFG ----- BRIEF plus GI
 BRIEF.OS --- BRIEF, OS only
 BRIEFG.OS -- BRIEF.OS plus GI
 BRIEF.PS --- BRIEF, PS only
 IBRIEF ----- BRIEF, indented with text labels
 IBRIEFG ----- IBRIEF plus GI
 IBRIEF.OS -- BRIEF, indented with text labels, OS only
 IBRIEFG.OS - IBRIEF.OS plus GI
 IBRIEF.PS -- BRIEF, indented with text labels, PS only

BIB ----- AN, ED, UP, EW, FS, TI, TIDE, TIFR, IN, PA, PAN, AG, AGN,
 OS, SO, DT, LA, DS, PIT, PI, OD, AI, PRAI, RLI, NTE, REP, REN

BIB.OS ----- BIB, OS only
 BIB.PS ----- BIB, PS only
 IBIB ----- BIB, indented with text labels
 IBIB.OS ----- BIB, indented with text labels, OS only
 IBIB.PS ----- BIB, indented with text labels, PS only
 BIBU ----- BIB, with German headers
 BIBU.OS ----- BIB, with German headers, OS only
 BIBU.PS ----- BIB, with German headers, PS only

STD ----- AN, ED, UP, EW, FS, TI, TIDE, TIFR, IN, PA, SO, DS, PIT, PI,
 OD, AI, PRAI, RLI, NTE, REP, REN, IC (ICM, ICS), ICA, ICI
 STD.OS ----- STD, OS only

STD.PS ----- STD, PS only
 ISTD ----- STD, indented with text labels
 ISTD.OS ---- STD, indented with text labels, OS only
 ISTD.PS ---- STD, indented with text labels, PS only
 STDU ----- STD, with German headers
 STDU.OS ---- STD, with German headers, OS only
 STDU.PS ---- STD, with German headers, PS only

 IND ----- ED, UP, EW, FS, IC (ICM, ICS), ICA, ICI
 IND.OS ----- IND, OS only
 IND.PS ----- IND, PS only

 TRI ----- TI, TIDE, TIFR, IC (ICM, ICS), ICA, ICI, CLMN, PGC, FA, GIS
 TRI.OS ----- TRI, OS only
 TRI.PS ----- TRI, PS only

 TX ----- DETD, CLM
 TX.OS ----- TX, OS only
 TX.PS ----- TX, PS only
 TXDE ----- DETDDE, CLMDE
 TXDE.OS ---- TXDE, OS only
 TXDE.PS ---- TXDE, PS only
 TXFR ----- DETDFR, CLMFR
 TXFR.OS ---- TXFR, OS only
 TXFR.PS ---- TXFR, PS only

To display a particular field or fields, enter the display field codes. For a list of display field codes, enter 'HELP DFIELDS' at an arrow prompt (=>). Examples of formats include: 'TI'; 'AN,TI,AU'; 'BIB,CT'; 'TI,CT'.
 The order of the terms in the formats is not important, but information will be displayed in the same order as the format specification.
 The same formats may be used with the DISPLAY ACC command to display the record for a specified accession number.

ENTER DISPLAY FORMAT (STD):ibib ab

L7 ANSWER 1 OF 1 EUROPATFULL COPYRIGHT 2004 WILA on STN

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 1210954 EUROPATFULL EW 200223 FS OS
 TITLE: NEW BIOCOMPATIBLE **POLYMER** SYSTEMS CARRYING
 TRIFLUSAL OR **HTB**.
 TRIFLUSAL ODER **HTB** TRAGENDE BIOKOMPATIBLE
POLYMERSYSTEME.
 NOUVEAUX SYSTEMES **POLYMERES** BIOCOMPATIBLES
 PORTEURS DE TRIFLUSAL OU DE **HTB**.
 INVENTOR(S): GALLARDO RUIZ, Alberto, Paseo de la Castellana, 127,
 E-28046 Madrid, ES;
 RODRIGUEZ CRESPO, Gema, Virgen del Sagrario, 25, E-28027
 Madrid, ES;
 SAN ROMAN DEL BARRIO, Julio, San Lorenzo del Escorial,
 38, E-28290 Las Matas, ES
 PATENT ASSIGNEE(S): J. URIACH & CIA. S.A., Dega Bahi, 59-67, E-08026
 Barcelona, ES
 PATENT ASSIGNEE NO: 1001490
 AGENT: Zumstein, Fritz, Dr. et al., Zumstein & Klingseisen
 Patentanwaelte Braeuhausstrasse 4, 80331 Muenchen, DE
 AGENT NUMBER: 13569
 OTHER SOURCE: BEPA2002048 EP 1210954 A1 0029
 SOURCE: Wila-EPZ-2002-H23-T1b
 DOCUMENT TYPE: Patent
 LANGUAGE: Anmeldung in Spanisch; Veroeffentlichung in Englisch;

Verfahren in Englisch
 DESIGNATED STATES: R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE; R AL; R LT; R LV; R MK; R RO; R SI
 PATENT INFO.PUB.TYPE: EPA1 EUROPAEISCHE PATENTANMELDUNG (Internationale Anmeldung)

PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 1210954	A1	20020605

'OFFENLEGUNGS' DATE:		20020605
APPLICATION INFO.:	EP 2000-956531	20000901
PRIORITY APPLN. INFO.:	ES 1999-2013	19990903
RELATED DOC. INFO.:	WO 00-ES335	000901 INTAKZ
	WO 0117578	010315 INTPNR

ABEN New biocompatible **polymeric** systems carrying triflusal or **HTB** are described which result from the **polymerization** of a monomer A of the **acrylic** or **vinyllic** type and carrying triflusal or **HTB**, wherein triflusal or **HTB** are linked to the remainder of the molecule of said monomer through an in vivo **hydrolysable covalent** bond, and optionally a second **polymerisable** monomer B. These new **polymeric** systems are useful as coating for synthetic biomaterials.

=> d his

(FILE 'HOME' ENTERED AT 15:59:25 ON 25 SEP 2004)

FILE 'CAPLUS, USPATFULL, JAPIO, EUROPATFULL, MEDLINE, BIOSIS, EMBASE, SCISEARCH' ENTERED AT 15:59:46 ON 25 SEP 2004

L1 976875 S (ACRYL? OR VINYL?) AND POLYMER?
 L2 878 S L1 AND (HTB OR TRIFUSAL)
 L3 376 S L2 AND HYDROLY?
 L4 202 S L3 AND COVALENT
 L5 129 S L3 AND COPOLYMER?
 L6 99 S L4 AND COPOLYMER?
 L7 1 S L6 AND (CARBOXYLIC ESTER)

=> s l6 and ((vascular prosthe?) or valve or stent or graft)
 L8 33 L6 AND ((VASCULAR PROSTHE?) OR VALVE OR STENT OR GRAFT)

=> d l8 1-33 ibib abs

L8 ANSWER 1 OF 33 USPATFULL on STN
 ACCESSION NUMBER: 2004:222041 USPATFULL
 TITLE: Antigen PIPA and antibodies that bind thereto
 INVENTOR(S): Mather, Jennie P., Millbrae, CA, UNITED STATES
 Li, Ronghao, Millbrae, CA, UNITED STATES
 Liang, Tony W., San Mateo, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004171814	A1	20040902
APPLICATION INFO.:	US 2003-713248	A1	20031113 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-426192P	20021113 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MORRISON & FOERSTER LLP, 755 PAGE MILL RD, PALO ALTO, CA, 94304-1018	

NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Page(s)
LINE COUNT: 3115

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Provided herein is disclosure about the identification and characterization of disease and cancer associated antigen PIPA. The invention also provides a family of monoclonal antibodies that bind to antigen PIPA, and methods of diagnosing and treating various human cancers and diseases that express PIPA.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 2 OF 33 USPATFULL on STN

ACCESSION NUMBER: 2004:145260 USPATFULL
TITLE: CD44-binding ligands
INVENTOR(S): Rondon, Isaac J., San Francisco, CA, UNITED STATES
Edge, Albert, Newton, MA, UNITED STATES
Kent, Rachel Baribault, Boxborough, MA, UNITED STATES
PATENT ASSIGNEE(S): DYAX CORPORATION (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004110933	A1	20040610
APPLICATION INFO.:	US 2003-663244	A1	20030915 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-410758P	20020913 (60)
	US 2003-469123P	20030509 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA, 02110	
NUMBER OF CLAIMS:	41	
EXEMPLARY CLAIM:	1	
LINE COUNT:	7240	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides, inter alia, CD44-binding proteins, including CD4-binding antibodies, antibody fragments, and pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such proteins. Methods of using the proteins to detect CD44 or to modulate a CD44-expressing cell, e.g., in a subject, are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 3 OF 33 USPATFULL on STN

ACCESSION NUMBER: 2004:50919 USPATFULL
TITLE: Heteromultimeric TNF ligand family members
INVENTOR(S): Hilbert, David M., Bethesda, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004038349	A1	20040226
APPLICATION INFO.:	US 2002-202062	A1	20020725 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-307838P	20010727 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,	

ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 37
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Page(s)
LINE COUNT: 14327

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compositions comprising heteromultimeric complexes, and particularly heterotrimeric complexes, of TNF ligand family members, and methods of using such complexes in the detection, prevention, and treatment of disease. Heteromultimeric TNF ligand polypeptide complexes comprising human TNF ligand polypeptides, including soluble forms of the extracellular domains, as well as membrane bound forms of TNF ligand polypeptides are provided. Heteromultimeric TNF ligand polypeptide complexes are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of heteromultimeric TNF ligand polypeptide complexes. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 4 OF 33 USPATFULL on STN

ACCESSION NUMBER: 2004:38077 USPATFULL
TITLE: Dopamine agonist formulations for enhanced central nervous system delivery
INVENTOR(S): Quay, Steven C., Edmonds, WA, UNITED STATES
PATENT ASSIGNEE(S): Nastech Pharmaceutical Company Inc, Hauppauge, NY (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004028613	A1	20040212
APPLICATION INFO.:	US 2001-891630	A1	20010625 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834		
NUMBER OF CLAIMS:	58		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Page(s)		
LINE COUNT:	8045		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pharmaceutical formulations are described comprising at least one dopamine receptor agonist and one or more mucosal delivery-enhancing agents for enhanced mucosal delivery of the dopamine receptor agonist. In one aspect, the mucosal delivery formulations and methods provide enhanced delivery of the dopamine receptor agonist to the central nervous system (CNS), for example by yielding dopamine receptor agonist concentrations in the cerebral spinal fluid of 5% or greater of the peak dopamine agonist concentrations in the blood plasma following administration to a mammalian subject. Exemplary formulations and methods within the invention utilize apomorphine as the dopamine receptor agonist. Other exemplary methods and formulations focus in intranasal administration of a dopamine receptor agonist. The formulations and methods of the invention are useful for treating a variety of diseases and conditions in mammalian subjects, including Parkinson's disease, male erectile dysfunction, female sexual dysfunction, among others. In alternate aspects, the mucosal delivery formulations and methods of the invention include one, or any combination of, mucosal delivery-enhancing agents selected from (a) aggregation inhibitory agents; (b) charge modifying agents; (c) pH control agents; (d) degradative enzyme inhibitors; (e) mucolytic or

mucus clearing agents; (f) ciliostatic agents; (g) membrane penetration-enhancing agents; (h) modulatory agents of epithelial junction physiology; (i) vasodilator agents; (j) selective transport-enhancing agents; and (k) stabilizing delivery vehicles, carriers, supports or complex-forming agents. These methods and formulations of the invention provide for significantly enhanced absorption of dopamine receptor agonists into or across a nasal mucosal barrier to a target site of action, for example the CNS.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 5 OF 33 USPATFULL on STN

ACCESSION NUMBER: 2003:319260 USPATFULL

TITLE: 28 human secreted proteins

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
 Ruben, Steven M., Olney, MD, UNITED STATES
 Li, Yi, Sunnyvale, CA, UNITED STATES
 Zeng, ZhiZhen, Landsdale, PA, UNITED STATES
 Kyaw, Hla, Frederick, MD, UNITED STATES
 Fischer, Carrie L., Burke, VA, UNITED STATES
 Li, Haodong, Gaithersburg, MD, UNITED STATES
 Soppet, Daniel R., Centreville, VA, UNITED STATES
 Gentz, Reiner L., Rockville, MD, UNITED STATES
 Wei, Ying-Fei, Berkeley, CA, UNITED STATES
 Moore, Paul A., Germantown, MD, UNITED STATES
 Young, Paul E., Gaithersburg, MD, UNITED STATES
 Greene, John M., Gaithersburg, MD, UNITED STATES
 Ferrie, Ann M., Painted Post, NY, UNITED STATES
 Hastings, Gregg A., Westlake Village, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003225009	A1	20031204
APPLICATION INFO.:	US 2002-58993	A1	20020130 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-852659, filed on 11 May 2001, PENDING Continuation-in-part of Ser. No. US 1998-152060, filed on 11 Sep 1998, GRANTED, Pat. No. US 6448230 Continuation-in-part of Ser. No. US 2001-852797, filed on 11 May 2001, PENDING Continuation-in-part of Ser. No. US 1998-152060, filed on 11 Sep 1998, GRANTED, Pat. No. US 6448230 Continuation-in-part of Ser. No. US 2001-853161, filed on 11 May 2001, PENDING Continuation-in-part of Ser. No. US 1998-152060, filed on 11 Sep 1998, GRANTED, Pat. No. US 6448230 Continuation-in-part of Ser. No. WO 1998-US4858, filed on 12 Mar 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-265583P	20010202 (60)
	US 2001-265583P	20010202 (60)
	US 2001-265583P	20010202 (60)
	US 2001-265583P	20010202 (60)
	US 1997-40762P	19970314 (60)
	US 1997-40710P	19970314 (60)
	US 1997-50934P	19970530 (60)
	US 1997-48100P	19970530 (60)
	US 1997-48357P	19970530 (60)
	US 1997-48189P	19970530 (60)
	US 1997-57765P	19970905 (60)
	US 1997-48970P	19970606 (60)
	US 1997-68368P	19971219 (60)

DOCUMENT TYPE:

Utility

FILE SEGMENT:

APPLICATION

LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 23

EXEMPLARY CLAIM: 1

LINE COUNT: 29452

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 33 USPATFULL on STN

ACCESSION NUMBER: 2003:279119 USPATFULL

TITLE: Monoclonal antibodies to membrane neutrokin- α

INVENTOR(S): Yu, Guo-Liang, Berkeley, CA, United States

Ebner, Reinhard, Gaithersburg, MD, United States

Ni, Jian, Rockville, MD, United States

Rosen, Craig A., Laytonsville, MD, United States

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6635482	B1	20031021
APPLICATION INFO.:	US 2000-589286		20000608 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-507968, filed on 22 Feb 2000 Continuation-in-part of Ser. No. US 1999-255794, filed on 23 Feb 1999 Continuation-in-part of Ser. No. US 1998-5874, filed on 12 Jan 1998 Continuation-in-part of Ser. No. WO 1996-US17957, filed on 25 Oct 1996		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-176015P	20000114 (60)
	US 1999-171626P	19991223 (60)
	US 1999-171108P	19991216 (60)
	US 1999-168624P	19991203 (60)
	US 1999-167239P	19991124 (60)
	US 1999-145824P	19990727 (60)
	US 1999-142659P	19990706 (60)
	US 1999-136784P	19990528 (60)
	US 1999-131673P	19990429 (60)
	US 1999-131278P	19990427 (60)
	US 1999-130696P	19990423 (60)
	US 1999-130412P	19990416 (60)
	US 1999-127598P	19990402 (60)
	US 1999-126599P	19990326 (60)
	US 1999-124097P	19990312 (60)
	US 1999-122388P	19990302 (60)
	US 1997-36100P	19970114 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Kemmerer, Elizabeth

ASSISTANT EXAMINER: Bunner, Bridget E.

LEGAL REPRESENTATIVE: Human Genome Sciences, Inc.

NUMBER OF CLAIMS: 32

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 34 Drawing Figure(s); 22 Drawing Page(s)

LINE COUNT: 15413

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a novel Neutrokin- α , and a splice variant thereof designated Neutrokin- α SV, polynucleotides and polypeptides which are members of the TNF family. In particular, isolated nucleic acid molecules are provided encoding the human Neutrokin- α and/or Neutrokin- α SV polypeptides, including soluble forms of the extracellular domain. Neutrokin- α and/or Neutrokin- α SV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of Neutrokin- α and/or Neutrokin- α SV activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 33 USPATFULL on STN

ACCESSION NUMBER: 2003:250423 USPATFULL

TITLE: Neutrokin- α and neutrokin- α splice variant

INVENTOR(S): Yu, Guo-Liang, Berkeley, CA, UNITED STATES

Ebner, Reinhard, Gaithersburg, MD, UNITED STATES

Ni, Jian, Germantown, MD, UNITED STATES

Rosen, Craig A., Laytonsville, MD, UNITED STATES

Ullrich, Stephen, Rockville, MD, UNITED STATES

Laird, Michael, Germantown, MD, UNITED STATES

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003175208	A1	20030918
APPLICATION INFO.:	US 2002-270487	A1	20021016 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-929493, filed on 15 Aug 2001, PENDING Continuation-in-part of Ser. No. US 2000-588947, filed on 8 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-589285, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589286, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589287, filed on 8 Jun 2000, GRANTED, Pat. No. US 6403770 Continuation-in-part of Ser. No. US 2000-589288, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-507968, filed on 22 Feb 2000, PENDING Continuation-in-part of Ser. No. US 1999-255794, filed on 23 Feb 1999, PENDING Continuation-in-part of Ser. No. US 2000-588947, filed on 8 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-589285, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589286, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589288, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-507968, filed on 22 Feb 2000, PENDING Continuation-in-part of Ser. No. US 1999-255794, filed on 23 Feb 1999, PENDING Continuation-in-part of Ser. No. US 1998-5874, filed on 12 Jan 1998, PENDING Continuation-in-part of Ser. No. WO 1996-US17957, filed on 25 Oct 1996, PENDING Continuation-in-part of Ser. No. US 1999-255794, filed on 23 Feb 1999, PENDING Continuation-in-part of Ser. No. US 1998-5874, filed on 12 Jan 1998, PENDING		

NUMBER

DATE

PRIORITY INFORMATION:	US 2001-329508P	20011017 (60)
	US 2001-329747P	20011018 (60)
	US 2001-330835P	20011031 (60)
	US 2001-331478P	20011116 (60)
	US 2001-336726P	20011207 (60)
	US 2002-368548P	20020401 (60)
	US 2000-225628P	20000815 (60)
	US 2000-227008P	20000823 (60)
	US 2000-234338P	20000922 (60)
	US 2000-240806P	20001017 (60)
	US 2000-250020P	20001130 (60)
	US 2001-276248P	20010316 (60)
	US 2001-293499P	20010525 (60)
	US 2001-296122P	20010607 (60)
	US 2001-304809P	20010713 (60)
	US 1999-122388P	19990302 (60)
	US 1999-124097P	19990312 (60)
	US 1999-126599P	19990326 (60)
	US 1999-127598P	19990402 (60)
	US 1999-130412P	19990416 (60)
	US 1999-130696P	19990423 (60)
	US 1999-131278P	19990427 (60)
	US 1999-131673P	19990429 (60)
	US 1999-136784P	19990528 (60)
	US 1999-142659P	19990706 (60)
	US 1999-145824P	19990727 (60)
	US 1999-167239P	19991124 (60)
	US 1999-168624P	19991203 (60)
	US 1999-171108P	19991216 (60)
	US 1999-171626P	19991223 (60)
	US 2000-176015P	20000114 (60)
	US 1999-122388P	19990302 (60)
	US 1999-124097P	19990312 (60)
	US 1999-126599P	19990326 (60)
	US 1999-127598P	19990402 (60)
	US 1999-130412P	19990416 (60)
	US 1999-130696P	19990423 (60)
	US 1999-131278P	19990427 (60)
	US 1999-131673P	19990429 (60)
	US 1999-136784P	19990528 (60)
	US 1999-142659P	19990706 (60)
	US 1999-145824P	19990727 (60)
	US 1999-167239P	19991124 (60)
	US 1999-168624P	19991203 (60)
	US 1999-171108P	19991216 (60)
	US 1999-171626P	19991223 (60)
	US 2000-176015P	20000114 (60)
	US 1997-36100P	19970114 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 44
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 27 Drawing Page(s)
LINE COUNT: 18884
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to nucleic acid molecules encoding Neutrokin- α and/or Neutrokin- α SV polypeptides, including soluble forms of the extracellular domain. Neutrokin- α and/or Neutrokin- α SV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind

Neutrokin-alpha and/or Neutrokin-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 8 OF 33 USPTFULL on STN

ACCESSION NUMBER: 2003:246895 USPTFULL
TITLE: Uses of VEGF-E
INVENTOR(S): Ferrara, Napoleone, San Francisco, CA, United States
Kuo, Sophia S., San Francisco, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6620784	B1	20030916
APPLICATION INFO.:	US 2000-723749		20001127 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-265686, filed on 10 Mar 1999, now patented, Pat. No. US 6455283 Continuation-in-part of Ser. No. US 1998-184216, filed on 2 Nov 1998, now abandoned Continuation-in-part of Ser. No. US 1998-40220, filed on 17 Mar 1998		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Saoud, Christine J.		
LEGAL REPRESENTATIVE:	Cui, Steven X.		
NUMBER OF CLAIMS:	5		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	14 Drawing Figure(s); 5 Drawing Page(s)		
LINE COUNT:	4371		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention involves the identification and preparation of vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel polypeptide related to vascular endothelial growth factor (VEGF) and bone morphogenetic protein 1. VEGF-E has homology to VEGF including conservation of the amino acids required for activity of VEGF. VEGF-E can be useful in wound repair, as well as in the generation and regeneration of tissue.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 9 OF 33 USPTFULL on STN

ACCESSION NUMBER: 2003:243796 USPTFULL
TITLE: Interleukin-1 homolog zilla7
INVENTOR(S): Sheppard, Paul O., Granite Falls, WA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003170205	A1	20030911
APPLICATION INFO.:	US 2002-132113	A1	20020424 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-286481P	20010425 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Gary E. Parker, ZymoGenetics, Inc., 1201 Eastlake Avenue East, Seattle, WA, 98102	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Page(s)	

LINE COUNT: 2432

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Homologs of interleukin-1, materials and methods for making them, compositions comprising them, and methods of using them are disclosed. The homologs are proteins comprising a sequence of amino acid residues as shown in SEQ ID NO:2 from residue 32 through residue 166. The proteins have inflammation modulating activity and are useful within related research and therapeutic applications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 10 OF 33 USPATFULL on STN

ACCESSION NUMBER: 2003:187916 USPATFULL

TITLE: Fhm, a novel member of the TNF ligand supergene family

INVENTOR(S): Hsu, Hailing, Moorpark, CA, UNITED STATES

Wooden, Scott Kenneth, Thousand Oaks, CA, UNITED STATES

Boyle, William James, Moorpark, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003129706	A1	20030710
APPLICATION INFO.:	US 2002-286696	A1	20021101 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-632287, filed on 3 Aug 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-147294P	19990804 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MARSHALL, GERSTEIN & BORUN, 6300 SEARS TOWER, 233 SOUTH WACKER, CHICAGO, IL, 60606-6357	
NUMBER OF CLAIMS:	71	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	5069	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a purified polynucleotide encoding a novel polypeptide, designated Fhm, which belongs to the TNF gene superfamily; to purified Fhm polypeptide molecules; to antibodies that bind Fhm; to materials comprising such molecules; and to methods of using such molecules.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 11 OF 33 USPATFULL on STN

ACCESSION NUMBER: 2003:166014 USPATFULL

TITLE: Polypeptides homologous to VEGF and BMP1

INVENTOR(S): Ferrara, Napoleone, San Francisco, CA, UNITED STATES

Kuo, Sophia S., San Francisco, CA, UNITED STATES

PATENT ASSIGNEE(S): Genentech, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003113870	A1	20030619
APPLICATION INFO.:	US 2002-178442	A1	20020619 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-265686, filed on 10 Mar 1999, GRANTED, Pat. No. US 6455283 Continuation-in-part of Ser. No. US 1998-184216, filed on 2 Nov 1998, ABANDONED Continuation-in-part of Ser. No. US 1998-40220, filed on 17 Mar 1998, GRANTED, Pat. No. US 6391311		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		

LEGAL REPRESENTATIVE: GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA,
94080
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 4273

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention involves the identification and preparation of
vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel
polypeptide related to vascular endothelial growth factor (VEGF) and
bone morphogenetic protein 1. VEGF-E has homology to VEGF including
conservation of the amino acids required for activity of VEGF. VEGF-E
can be useful in wound repair, as well as in the generation and
regeneration of tissue.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 12 OF 33 USPATFULL on STN

ACCESSION NUMBER: 2003:129800 USPATFULL
TITLE: Diagnostic methods using antibodies to Neutrokin-alpha
INVENTOR(S): Yu, Guo-Liang, Berkeley, CA, United States
Ebner, Reinhard, Gaithersburg, MD, United States
Ni, Jian, Rockville, MD, United States
Rosen, Craig A., Laytonsville, MD, United States
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, United
States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6562579	B1	20030513
APPLICATION INFO.:	US 2000-588947		20000608 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-507968, filed on 22 Feb 2000 Continuation-in-part of Ser. No. US 1999-255794, filed on 23 Feb 1999 Continuation-in-part of Ser. No. US 1998-5874, filed on 12 Jan 1998 Continuation-in-part of Ser. No. WO 1996-US17957, filed on 25 Oct 1996		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-36100P	19970114 (60)
	US 1999-122388P	19990302 (60)
	US 1999-124097P	19990312 (60)
	US 1999-126599P	19990326 (60)
	US 1999-127598P	19990402 (60)
	US 1999-130412P	19990416 (60)
	US 1999-130696P	19990423 (60)
	US 1999-131278P	19990427 (60)
	US 1999-131673P	19990429 (60)
	US 1999-136784P	19990528 (60)
	US 1999-142659P	19990706 (60)
	US 1999-145824P	19990727 (60)
	US 1999-167239P	19991124 (60)
	US 1999-168624P	19991203 (60)
	US 1999-171108P	19991216 (60)
	US 1999-171626P	19991223 (60)
	US 2000-176015P	20000114 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Byler, Yvonne
ASSISTANT EXAMINER: Prasad, Sarada C
LEGAL REPRESENTATIVE: Human Genome Sciences, Inc
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 33 Drawing Figure(s); 22 Drawing Page(s)

LINE COUNT: 15469

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a novel Neutrokin- α , and a splice variant thereof designated Neutrokin- α SV, polynucleotides and polypeptides which are members of the TNF family. In particular, isolated nucleic acid molecules are provided encoding the human Neutrokin- α and/or Neutrokin- α SV polypeptides, including soluble forms of the extracellular domain. Neutrokin- α and/or Neutrokin- α SV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of Neutrokin- α and/or Neutrokin- α SV activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 13 OF 33 USPTAFULL on STN

ACCESSION NUMBER: 2003:120997 USPTAFULL

TITLE: 25 human prostate and prostate cancer associated proteins

INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003083481	A1	20030501
APPLICATION INFO.:	US 2002-36542	A1	20020107 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2000-US19666, filed on 20 Jul 2000, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-144972P	19990721 (60)
	US 1999-148681P	19990813 (60)
	US 1999-149173P	19990817 (60)
	US 1999-158004P	19991006 (60)
	US 2000-194689P	20000405 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 24

EXEMPLARY CLAIM: 1

LINE COUNT: 26241

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to newly identified prostate or prostate cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "prostate antigens" or alternatively "prostate cancer antigens", and the use of such prostate or prostate cancer antigens for detecting disorders of the prostate, particularly the presence of prostate cancer and prostate cancer metastases. This invention relates to prostate or prostate cancer antigens as well as vectors, host cells, antibodies directed to prostate or prostate cancer antigens and the recombinant methods and synthetic methods for producing the same. Also provided are diagnostic methods for detecting, treating, preventing and/or prognosing disorders of the prostate, particularly prostate cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of prostate or prostate

cancer antigens of the invention. The present invention further relates to inhibiting the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 14 OF 33 USPATFULL on STN

ACCESSION NUMBER: 2003:86317 USPATFULL

TITLE: Polynucleotide encoding a novel human potassium channel alpha-subunit, K+alphaM1, and variants thereof

INVENTOR(S): Feder, John N., Belle Mead, NJ, UNITED STATES
Lee, Liana M., North Brunswick, NJ, UNITED STATES
Chen, Jian, Princeton, NJ, UNITED STATES
Jackson, Donald, Lawrenceville, NJ, UNITED STATES
Ramanathan, Chandra, Wallingford, CT, UNITED STATES
Siemers, Nathan, Pennington, NJ, UNITED STATES
Chang, Han, Princeton Junction, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003059923	A1	20030327
APPLICATION INFO.:	US 2001-999220	A1	20011101 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-245383P	20001102 (60)
	US 2000-257780P	20001221 (60)
	US 2001-269854P	20010220 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000

NUMBER OF CLAIMS: 37

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 30 Drawing Page(s)

LINE COUNT: 16037

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding K+alphaM1 polypeptides, fragments and homologues thereof. The invention also provides novel polynucleotides encoding the K+alphaM1 variant polypeptides, K+alphaM1.v1 and K+alphaM1.v2, in addition to fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel K+alphaM1, K+alphaM1.v1, and K+alphaM1.v2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 15 OF 33 USPATFULL on STN

ACCESSION NUMBER: 2003:49537 USPATFULL

TITLE: Applications of light-emitting nanoparticles

INVENTOR(S): Korgel, Brian A., Round Rock, TX, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003034486	A1	20030220
APPLICATION INFO.:	US 2002-109608	A1	20020328 (10)

NUMBER	DATE
--------	------

 PRIORITY INFORMATION: US 2001-302594P 20010702 (60)
 DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: ERIC B. MEYERTONS, CONLEY, ROSE & TAYON, P.C., P.O BOX
 398, AUSTIN, TX, 78767-0398
 NUMBER OF CLAIMS: 598
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 29 Drawing Page(s)
 LINE COUNT: 4628

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for the production of a robust, chemically stable, crystalline, passivated nanoparticle and composition containing the same, that emit light with high efficiencies and size-tunable and excitation energy tunable color. The methods include the thermal degradation of a precursor molecule in the presence of a capping agent at high temperature and elevated pressure. A particular composition prepared by the methods is a passivated silicon nanoparticle composition displaying discrete optical transitions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 16 OF 33 USPATFULL on STN

ACCESSION NUMBER: 2003:47644 USPATFULL
 TITLE: Fhm, a novel member of the TNF ligand supergene family
 INVENTOR(S): Hsu, Hailing, Moorpark, CA, United States
 Wooden, Scott Kenneth, Thousand Oaks, CA, United States
 Boyle, William James, Moorpark, CA, United States
 PATENT ASSIGNEE(S): Amgen Inc., Thousand Oaks, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6521422	B1	20030218
APPLICATION INFO.:	US 2000-632287		20000803 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-147294P	19990804 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Eyler, Yvonne	
ASSISTANT EXAMINER:	Andres, Janet L.	
LEGAL REPRESENTATIVE:	Marshall, Gerstein & Borun	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	4749	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a purified polynucleotide encoding a novel polypeptide, designated Fhm, which belongs to the TNF gene superfamily; to purified Fhm polypeptide molecules; to antibodies that bind Fhm; to materials comprising such molecules; and to methods of using such molecules.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 17 OF 33 USPATFULL on STN

ACCESSION NUMBER: 2003:30870 USPATFULL
 TITLE: Angiogenesis-modulating compositions and uses
 INVENTOR(S): Ling, Leona E., Winchester, MA, UNITED STATES
 Sanicola-Nadel, Michele, Winchester, MA, UNITED STATES

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2003022819 A1 20030130
APPLICATION INFO.: US 2001-883848 A1 20010618 (9)

NUMBER DATE

PRIORITY INFORMATION: US 2000-211919P 20000616 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ROPES & GRAY, ONE INTERNATIONAL PLACE, BOSTON, MA,
02110-2624
NUMBER OF CLAIMS: 34
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 8945
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Hedgehog agonists and antagonists can be used to regulate angiogenesis,
and have utility in treating tissue repair and cancer, and to prevent
angiogenesis driven pathologies.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 18 OF 33 USPATFULL on STN
ACCESSION NUMBER: 2003:3266 USPATFULL
TITLE: Light-emitting nanoparticles and method of making same
INVENTOR(S): Korgel, Brian A., Round Rock, TX, UNITED STATES
Johnston, Keith P., Austin, TX, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2003003300 A1 20030102
APPLICATION INFO.: US 2002-109578 A1 20020328 (10)

NUMBER DATE

PRIORITY INFORMATION: US 2001-302594P 20010702 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ERIC B. MEYERTONS, CONLEY, ROSE & TAYON, P.C., P.O. BOX
398, AUSTIN, TX, 78767-0398
NUMBER OF CLAIMS: 598
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 31 Drawing Page(s)
LINE COUNT: 4619
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for the production of a robust, chemically stable, crystalline,
passivated nanoparticle and composition containing the same, that emit
light with high efficiencies and size-tunable and excitation energy
tunable color. The methods include the thermal degradation of a
precursor molecule in the presence of a capping agent at high
temperature and elevated pressure. A particular composition prepared by
the methods is a passivated silicon nanoparticle composition displaying
discrete optical transitions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 19 OF 33 USPATFULL on STN
ACCESSION NUMBER: 2002:246563 USPATFULL
TITLE: Nucleic acids encoding vascular endothelial cell growth
factor-E (VEGF-E)
INVENTOR(S): Ferrara, Napoleone, San Francisco, CA, United States
Kuo, Sophia S., San Francisco, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6455283	B1	20020924
APPLICATION INFO.:	US 1999-265686		19990310 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1998-184216, filed on 2 Nov 1998, now abandoned Continuation-in-part of Ser. No. US 1998-40220, filed on 17 Mar 1998		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Spector, Lorraine		
LEGAL REPRESENTATIVE:	Cui, Steven X.		
NUMBER OF CLAIMS:	7		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	14 Drawing Figure(s); 5 Drawing Page(s)		
LINE COUNT:	4363		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention involves the identification and preparation of vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel polypeptide related to vascular endothelial growth factor (VEGF) and bone morphogenetic protein 1. VEGF-E has homology to VEGF including conservation of the amino acids required for activity of VEGF. VEGF-E can be useful in wound repair, as well as in the generation and regeneration of tissue.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 20 OF 33 USPATFULL on STN

ACCESSION NUMBER: 2002:235521 USPATFULL
 TITLE: Process for ex vivo formation of mammalian bone and uses thereof
 INVENTOR(S): Kale, Sujata, Boston, MA, UNITED STATES
 Long, Michael W., Northville, MI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002127711	A1	20020912
APPLICATION INFO.:	US 2000-753043	A1	20001227 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Steven L. Highlander, Fulbright & Jaworski L.L.P., 600 Congress Avenue Suite 2400, Austin, TX, 78701		
NUMBER OF CLAIMS:	38		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	10 Drawing Page(s)		
LINE COUNT:	3032		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention concerns methods for the ex vivo formation of mammalian bone and subsequent uses of the bone. A critical and distinguishing feature of the present invention are defined tissue culture conditions and factors resulting in the formation of bone cell spheroids. The invention also provides for methods of implanting into subjects the ex vivo formed bone. Also described are methods for genetically altering the bone cell spheroids to affect bone formation, identification of candidate modulators of bone formation, and identification of genes involved in bone formation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 21 OF 33 USPATFULL on STN

ACCESSION NUMBER: 2002:213736 USPATFULL
 TITLE: Neutrokin-alpha and Neutrokin-alpha splice variant
 INVENTOR(S): Yu, Guo-Liang, Berkeley, CA, UNITED STATES
 Ebner, Reinhard, Gaithersburg, MD, UNITED STATES

PATENT ASSIGNEE(S): Ni, Jian, Germantown, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ullrich, Stephen, Rockville, MD, UNITED STATES
Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002115112	A1	20020822
APPLICATION INFO.:	US 2001-929493	A1	20010815 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-588947, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589285, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589286, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589287, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-586288, filed on 2 Jun 2000, PATENTED Continuation-in-part of Ser. No. US 2000-507968, filed on 22 Feb 2000, PENDING Continuation-in-part of Ser. No. US 1999-255794, filed on 23 Feb 1999, PENDING Continuation-in-part of Ser. No. US 1999-255794, filed on 23 Feb 1999, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-225628P	20000815 (60)
	US 2000-227008P	20000823 (60)
	US 2000-234338P	20000922 (60)
	US 2000-240806P	20001017 (60)
	US 2000-250020P	20001130 (60)
	US 2001-276248P	20010316 (60)
	US 2001-293499P	20010525 (60)
	US 2001-296122P	20010607 (60)
	US 2001-304809P	20010713 (60)
	US 1999-122388P	19990302 (60)
	US 1999-124097P	19990312 (60)
	US 1999-126599P	19990326 (60)
	US 1999-127598P	19990402 (60)
	US 1999-130412P	19990416 (60)
	US 1999-130696P	19990423 (60)
	US 1999-131278P	19990427 (60)
	US 1999-131673P	19990429 (60)
	US 1999-136784P	19990528 (60)
	US 1999-142659P	19990706 (60)
	US 1999-145824P	19990727 (60)
	US 1999-167239P	19991124 (60)
	US 1999-168624P	19991203 (60)
	US 1999-171108P	19991216 (60)
	US 1999-171626P	19991223 (60)
	US 2000-176015P	20000114 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 117
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Page(s)
LINE COUNT: 18178

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to nucleic acid molecules encoding Neutrokin- α and/or Neutrokin- α SV polypeptides, including soluble forms of the extracellular domain. Neutrokin- α and/or Neutrokin- α SV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention

further relates to antibodies or portions thereof that specifically bind Neutrokin- α and/or Neutrokin- α SV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 22 OF 33 USPATFULL on STN

ACCESSION NUMBER: 2002:137146 USPATFULL

TITLE: Antibodies to neutrokin- α

INVENTOR(S): Yu, Guo-Liang, Berkeley, CA, United States

Ebner, Reinhard, Gaithersburg, MD, United States

Ni, Jian, Rockville, MD, United States

Rosen, Craig A., Laytonville, MD, United States

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6403770	B1	20020611
APPLICATION INFO.:	US 2000-589287		20000608 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-507968, filed on 22 Feb 2000 Continuation-in-part of Ser. No. US 1999-255794, filed on 23 Feb 1999 Continuation-in-part of Ser. No. US 1998-5874, filed on 12 Jan 1998 Continuation-in-part of Ser. No. WO 1996-US17957, filed on 25 Oct 1996		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-176015P	20000114 (60)
	US 1999-171626P	19991223 (60)
	US 1999-171108P	19991216 (60)
	US 1999-168624P	19991203 (60)
	US 1999-167239P	19991124 (60)
	US 1999-145824P	19990727 (60)
	US 1999-142659P	19990706 (60)
	US 1999-136784P	19990528 (60)
	US 1999-131673P	19990429 (60)
	US 1999-131278P	19990427 (60)
	US 1999-130696P	19990423 (60)
	US 1999-130412P	19990416 (60)
	US 1999-127598P	19990402 (60)
	US 1999-126599P	19990326 (60)
	US 1999-124097P	19990312 (60)
	US 1999-122388P	19990302 (60)
	US 1997-36100P	19970114 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Kunz, Gary L.

ASSISTANT EXAMINER: Prasad, Sarada C

LEGAL REPRESENTATIVE: Human Genome Sciences, Inc.

NUMBER OF CLAIMS: 292

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 11 Drawing Figure(s); 22 Drawing Page(s)

LINE COUNT: 15430

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a novel Neutrokin- α , and a splice variant thereof designated Neutrokin- α SV, polynucleotides and polypeptides which are members of the TNF family. In particular, isolated nucleic acid molecules are provided encoding the human Neutrokin- α and/or Neutrokin- α SV polypeptides, including

soluble forms of the extracellular domain. Neutrokin-alpha and/or Neutrokin-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of Neutrokin-alpha and/or Neutrokin-alphaSV activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 23 OF 33 USPATFULL on STN

ACCESSION NUMBER: 2002:98856 USPATFULL

TITLE: Pharmaceuticals and apparatus providing diagnosis and selective tissue necrosis

INVENTOR(S): Mills, Randell L., Cochranville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002051751	A1	20020502
APPLICATION INFO.:	US 2001-819141	A1	20010327 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-454012, filed on 30 May 1995, GRANTED, Pat. No. US 6224848 Continuation of Ser. No. US 1992-950973, filed on 23 Sep 1992, ABANDONED Continuation of Ser. No. US 1987-55591, filed on 28 May 1987, ABANDONED Continuation-in-part of Ser. No. US 1986-849046, filed on 7 Apr 1986, GRANTED, Pat. No. US 4815448 Continuation-in-part of Ser. No. US 1985-713448, filed on 19 Mar 1985, GRANTED, Pat. No. US 4815447		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109		
NUMBER OF CLAIMS:	70		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	17 Drawing Page(s)		
LINE COUNT:	3411		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pharmaceuticals and Apparatus used in combination for diagnosis and tissue necrosis applicable to provide effective and selective therapy using the Mossbauer absorption phenomenon. Selected pharmaceutical compounds containing a radiation absorber isotope are administered to a tissue and excited by a radiation source which provides energy at the corresponding resonant Mossbauer absorption frequency of isotope containing pharmaceutical, where excitation effects nuclear transitions to cause highly selective energy absorption in the selected target tissue. For diagnostic purposes, de-excitation fluorescence of the isotope is monitored. For therapeutic purposes, the energy is converted to particle radiation by the isotope at the target tissue by internal conversion followed by an Auger electron cascade which results in radiolysis of DNA resulting in lethal double strand breaks in the DNA molecules of the target tissue. The tissue selectivity is achieved by providing a Mossbauer absorption frequency of the target tissue which differs from that of surrounding tissue. The difference in frequency is due to the properties of the pharmaceutical, and/or an imposition of external magnetic fields or narrow beam ultrasonic power at the site of the target tissue. The magnitude of radiation absorption at the resonant Mossbauer frequency for the target tissue is of the order of one million times the absorption of surrounding nontarget tissue, which has a different Mossbauer absorption frequency, thereby producing considerably reduced side effects in comparison to conventional chemotherapy or radiation therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 24 OF 33 USPATFULL on STN

ACCESSION NUMBER: 2002:92245 USPATFULL

TITLE: Human genome-derived single exon nucleic acid probes
useful for gene expression analysis

INVENTOR(S): Penn, Sharron Gaynor, San Mateo, CA, UNITED STATES
Rank, David Russell, Fremont, CA, UNITED STATES
Chen, Wensheng, Mountain View, CA, UNITED STATES
Hanzel, David Kagen, Palo Alto, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002048763	A1	20020425
APPLICATION INFO.:	US 2001-864761	A1	20010523 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-774203, filed on 29 Jan 2001, PENDING Continuation-in-part of Ser. No. US 2000-632366, filed on 3 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-608408, filed on 30 Jun 2000, PENDING Continuation-in-part of Ser. No. WO 2001-US666, filed on 30 Jan 2001, UNKNOWN Continuation-in-part of Ser. No. WO 2001-US667, filed on 30 Jan 2001, UNKNOWN Continuation-in-part of Ser. No. WO 2001-US664, filed on 30 Jan 2001, UNKNOWN Continuation-in-part of Ser. No. WO 2001-US669, filed on 30 Jan 2001, UNKNOWN Continuation-in-part of Ser. No. WO 2001-US665, filed on 30 Jan 2001, UNKNOWN Continuation-in-part of Ser. No. WO 2001-US668, filed on 30 Jan 2001, UNKNOWN Continuation-in-part of Ser. No. WO 2001-US663, filed on 30 Jan 2001, UNKNOWN Continuation-in-part of Ser. No. WO 2001-US662, filed on 30 Jan 2001, UNKNOWN Continuation-in-part of Ser. No. WO 2001-US661, filed on 30 Jan 2001, UNKNOWN Continuation-in-part of Ser. No. WO 2001-US670, filed on 30 Jan 2001, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2000-242636	20001004
	US 2000-180312P	20000204 (60)
	US 2000-207456P	20000526 (60)
	US 2000-234687P	20000921 (60)
	US 2000-236359P	20000927 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FISH & NEAVE, 1251 AVENUE OF THE AMERICAS, 50TH FLOOR, NEW YORK, NY, 10020-1105	
NUMBER OF CLAIMS:	58	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	10 Drawing Page(s)	
LINE COUNT:	9057	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and apparatus for predicting, confirming and displaying
functional regions from genomic sequence data are used to identify
16,834 unique human genome-derived single exon probes useful for gene
expression analysis, particularly gene expression analysis by
microarray. Also presented are genome-derived single exon microarrays
that include such probes, peptides encoded by the exons, and antibodies
thereto.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 25 OF 33 USPATFULL on STN

ACCESSION NUMBER: 2002:12261 USPATFULL

TITLE: Uteroglobin-like polynucleotides, polypeptides, and

antibodies
INVENTOR(S): Ni, Jian, Germantown, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002006640	A1	20020117
APPLICATION INFO.:	US 2001-846258	A1	20010502 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2000-US30326, filed on 3 Nov 2000, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-163395P	19991104 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
LINE COUNT:	12076	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel human uteroglobin-like polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human uteroglobin-like polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human uteroglobin-like polypeptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 26 OF 33 USPATFULL on STN
ACCESSION NUMBER: 2001:63226 USPATFULL
TITLE: Pharmaceuticals providing diagnosis and selective tissue necrosis using Mossbauer absorber atom
INVENTOR(S): Mills, Randell L., R.D. 2, Cochranville, PA, United States 19330

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6224848	B1	20010501
APPLICATION INFO.:	US 1995-454012		19950530 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1992-950973, filed on 23 Sep 1992, now abandoned Continuation of Ser. No. US 1987-55591, filed on 28 May 1987, now abandoned Continuation-in-part of Ser. No. US 1986-849046, filed on 7 Apr 1986, now patented, Pat. No. US 4815448 Continuation-in-part of Ser. No. US 1985-713448, filed on 19 Mar 1985, now patented, Pat. No. US 4815447		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Dudash, Diana		
ASSISTANT EXAMINER:	Hartley, Michael G.		
LEGAL REPRESENTATIVE:	Lahive & Cockfield, LLP, DeConti, Giulio A., Triano, III, Nicholas P.		
NUMBER OF CLAIMS:	9		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	22 Drawing Figure(s); 17 Drawing Page(s)		
LINE COUNT:	3073		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pharmaceuticals and Apparatus used in combination for diagnosis and tissue necrosis applicable to provide effective and selective therapy using the Mossbauer absorption phenomenon. Selected pharmaceutical

compounds containing a radiation absorber isotope are administered to a tissue and excited by a radiation source which provides energy at the corresponding resonant Mossbauer absorption frequency of isotope containing pharmaceutical, where excitation effects nuclear transitions to cause highly selective energy absorption in the selected target tissue. For diagnostic purposes, de-excitation fluorescence of the isotope is monitored. For therapeutic purposes, the energy is converted to particle radiation by the isotope at the target tissue by internal conversion followed by an Auger electron cascade which results in radiolysis of DNA resulting in lethal double strand breaks in the DNA molecules of the target tissue.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 27 OF 33 USPATFULL on STN

ACCESSION NUMBER: 1999:106108 USPATFULL

TITLE: Compositions and therapeutic methods using morphogenic proteins and stimulatory factors

INVENTOR(S): Lee, John C., San Antonio, TX, United States

Yeh, Lee-Chuan C., San Antonio, TX, United States

PATENT ASSIGNEE(S): Stryker Corporation, Kalamazoo, MI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5948428		19990907
APPLICATION INFO.:	US 1996-761468		19961206 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-570752, filed on 12 Dec 1995		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Azpuru, Carlos		
LEGAL REPRESENTATIVE:	Fish & Neave, Haley, James F., Ruskin, Barbara A.		
NUMBER OF CLAIMS:	78		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	17 Drawing Figure(s); 16 Drawing Page(s)		
LINE COUNT:	3767		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides pharmaceutical compositions comprising a morphogenic protein stimulatory factor (MPSF) for improving the tissue inductive activity of morphogenic proteins, particularly those belonging to the BMP protein family. Methods for improving the tissue inductive activity of a morphogenic protein in a mammal using those compositions are provided. This invention also provides implantable morphogenic devices comprising a morphogenic protein and a MPSF disposed within a carrier, that are capable of inducing tissue formation in allogeneic and xenogeneic implants. Methods for inducing local tissue formation from a progenitor cell in a mammal using those devices are also provided. A method for accelerating allograft repair in a mammal using morphogenic devices is provided. This invention also provides a prosthetic device comprising a prosthesis coated with a morphogenic protein and a MPSF, and a method for promoting in vivo integration of an implantable prosthetic device to enhance the bond strength between the prosthesis and the existing target tissue at the joining site. Methods of treating tissue degenerative conditions in a mammal using the pharmaceutical compositions are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 28 OF 33 USPATFULL on STN

ACCESSION NUMBER: 1998:72592 USPATFULL

TITLE: Sensory and motor neuron derived factor (SMDF)

INVENTOR(S): Ho, Wei-Hsien, Palo Alto, CA, United States

Osheroff, Phyllis L., Woodside, CA, United States

PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5770567		19980623
APPLICATION INFO.:	US 1994-339517		19941114 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Hutzell, Paula K.		
ASSISTANT EXAMINER:	Gucker, Stephen		
LEGAL REPRESENTATIVE:	Lee, Wendy M.		
NUMBER OF CLAIMS:	22		
EXEMPLARY CLAIM:	2		
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 4 Drawing Page(s)		
LINE COUNT:	3771		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Isolated SMDF, isolated DNA encoding SMDF, and recombinant or synthetic methods of preparing SMDF are disclosed. SMDF contains a β -type EGF-like domain and a N-terminal sequence which is distinct from all neuregulins reported so far. SMDF, when expressed in recombinant cell culture, activates tyrosine phosphorylation of the HER2/neu receptor in human breast cancer cells and displays mitogenic activity on Schwann cells. Northern blot and in situ hybridization analysis show that SMDF differs from other neuregulins in that it is nervous tissue specific, and is very highly expressed, in comparison to other neuregulins, in the human and rat spinal cord motor neurons and sensory neurons.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 29 OF 33 USPATFULL on STN

ACCESSION NUMBER: 1998:65003 USPATFULL
TITLE: Sensory and motor neuron derived factor (SMDF)
INVENTOR(S): Ho, Wei-Hsien, Palo Alto, CA, United States
Osheroff, Phyllis L., Woodside, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5763213		19980609
APPLICATION INFO.:	US 1995-428298		19950425 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-339517, filed on 14 Nov 1994		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Hutzell, Paula K.		
ASSISTANT EXAMINER:	Gucker, Stephen		
LEGAL REPRESENTATIVE:	Lee, Wendy M.		
NUMBER OF CLAIMS:	31		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 4 Drawing Page(s)		
LINE COUNT:	3837		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Isolated SMDF, isolated DNA encoding SMDF, and recombinant or synthetic methods of preparing SMDF are disclosed. SMDF contains a β -type EGF-like domain and a N-terminal sequence which is distinct from all neuregulins reported so far. SMDF, when expressed in recombinant cell culture, activates tyrosine phosphorylation of the HER2/neu receptor in human breast cancer cells and displays mitogenic activity on Schwann cells. Northern blot and in situ hybridization analysis show that SMDF differs from other neuregulins in that it is nervous tissue specific, and is very highly expressed, in comparison to other neuregulins, in the human and rat spinal cord motor neurons and sensory neurons.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 30 OF 33 USPATFULL on STN

ACCESSION NUMBER: 1998:57880 USPATFULL

TITLE: Methods involving sensory and motor neuron derived factor (SMDF)

INVENTOR(S): Ho, Wei-Hsien, Palo Alto, CA, United States
Osherooff, Phyllis L., Woodside, CA, United States

PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5756456		19980526
APPLICATION INFO.:	US 1995-428927		19950425 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-339517, filed on 14 Nov 1994		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Mutzell, Paula R.		
ASSISTANT EXAMINER:	Gucker, Stephen		
LEGAL REPRESENTATIVE:	Lee, Wendy M.		
NUMBER OF CLAIMS:	17		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 4 Drawing Page(s)		
LINE COUNT:	3757		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for activating the HER2 receptor comprising contacting a cell which expresses this receptor with SMDF polypeptides is discussed. A method for enhancing differentiation and/or proliferation of a cell using SMDF polypeptides is also disclosed. These methods may be performed in vitro or in vivo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 31 OF 33 USPATFULL on STN

ACCESSION NUMBER: 97:83613 USPATFULL

TITLE: Antibodies to SMDF

INVENTOR(S): Ho, Wei-Hsien, Palo Alto, CA, United States
Osherooff, Phyllis L., Woodside, CA, United States

PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5667780		19970916
APPLICATION INFO.:	US 1995-428926		19950425 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-339517, filed on 14 Nov 1994		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Feisee, Lila		
ASSISTANT EXAMINER:	Johnson, Nancy A.		
LEGAL REPRESENTATIVE:	Lee, Wendy M.		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 4 Drawing Page(s)		
LINE COUNT:	3743		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Isolated SMDF, isolated DNA encoding SMDF, and antibodies to SMDF are disclosed. SMDF contains a β -type EGF-like domain and a N-terminal sequence which is distinct from all neuregulins reported so far. SMDF, when expressed in recombinant cell culture, activates tyrosine

phosphorylation of the HER2/neu receptor in human breast cancer cells and displays mitogenic activity on Schwann cells. Northern blot and in situ hybridization analysis show that SMDF differs from other neuregulins in that it is nervous tissue specific, and is very highly expressed, in comparison to other neuregulins, in the human and rat spinal cord motor neurons and sensory neurons.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 32 OF 33 EUROPATFULL COPYRIGHT 2004 WILA on STN

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 1210954 EUROPATFULL EW 200223 FS OS
TITLE: NEW BIOCOMPATIBLE **POLYMER** SYSTEMS CARRYING
TRIFLUSAL OR **HTB**.
TRIFLUSAL ODER **HTB** TRAGENDE BIOKOMPATIBLE
POLYMERSYSTEME.
NOUVEAUX SYSTEMES **POLYMERES** BIOCOMPATIBLES
PORTEURS DE TRIFLUSAL OU DE **HTB**.
INVENTOR(S): GALLARDO RUIZ, Alberto, Paseo de la Castellana, 127,
E-28046 Madrid, ES;
RODRIGUEZ CRESPO, Gema, Virgen del Sagrario, 25, E-28027
Madrid, ES;
SAN ROMAN DEL BARRIO, Julio, San Lorenzo del Escorial,
38, E-28290 Las Matas, ES
PATENT ASSIGNEE(S): J. URIACH & CIA. S.A., Dega Bahi, 59-67, E-08026
Barcelona, ES
PATENT ASSIGNEE NO: 1001490
AGENT: Zumstein, Fritz, Dr. et al., Zumstein & Klingseisen
Patentanwaelte Braeuhausstrasse 4, 80331 Muenchen, DE
13569
AGENT NUMBER:
OTHER SOURCE: BEPA2002048 EP 1210954 A1 0029
SOURCE: Wila-EPZ-2002-H23-T1b
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Spanisch; Veroeffentlichung in Englisch;
Verfahren in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R
GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R
SE; R AL; R LT; R LV; R MK; R RO; R SI
PATENT INFO.PUB.TYPE: EPA1 EUROPAEISCHE PATENTANMELDUNG (Internationale
Anmeldung)
PATENT INFORMATION:
PATENT NO KIND DATE

EP 1210954 A1 20020605
'OFFENLEGUNGS' DATE: 20020605
APPLICATION INFO.: EP 2000-956531 20000901
PRIORITY APPLN. INFO.: ES 1999-2013 19990903
RELATED DOC. INFO.: WO 00-ES335 000901 INTAKZ
WO 0117578 010315 INTPNR

L8 ANSWER 33 OF 33 EUROPATFULL COPYRIGHT 2004 WILA on STN

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 871471 EUROPATFULL EW 200426 FS PS
TITLE: COMPOSITIONS USING MORPHOGENIC PROTEINS AND STIMULATORY
FACTORS.
ZUSAMMENSETZUNGEN UNTER VERWENDUNG VON MORPHOGENEN
PROTEINEN UND STIMULATIONSFAKTOREN.
COMPOSITIONS THERAPEUTIQUES METTANT EN OEVRE DES
PROTEINES MORPHOGENIQUES ET DES FACTEURS DE STIMULATION.
INVENTOR(S): LEE, John, C., 1119 Haltown Drive, San Antonio, TX

78213, US;
 YEH, Lee-Chuan, C., 8027 Indian Bend, San Antonio, TX
 78250, US
 PATENT ASSIGNEE(S): STRYKER CORPORATION, 2725 Fairfield Road, Kalamazoo, MI
 49001, US
 PATENT ASSIGNEE NO: 558084
 AGENT: VOSSIUS & PARTNER, Siebertstrasse 4, 81675 Muenchen, DE
 AGENT NUMBER: 100314
 OTHER SOURCE: MEPB2004027 EP 0871471 B1 0060
 SOURCE: Wila-EPS-2004-H26-T1
 DOCUMENT TYPE: Patent
 LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
 DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FI; R FR; R GB; R
 GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE
 PATENT INFO.PUB.TYPE: EPB1 EUROPÄISCHE PATENTSCHRIFT (Internationale
 Anmeldung)
 PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 871471	B1	20040623
		19981021
EP 1996-944806		19961211
US 1995-570752		19951212
WO 96-US19876	961211	INTAKZ
WO 1997021447	970619	INTPNR
EP 436469 A	EP 514720	A
WO 92-09697 A	WO 92-21365	A
WO 93-05823 A	US 5324819	A

'OFFENLEGUNGS' DATE:
 APPLICATION INFO.:
 PRIORITY APPLN. INFO.:
 RELATED DOC. INFO.:
 REFERENCE PAT. INFO.:
 REF. NON-PATENT-LIT.: DATABASE WPI Section Ch, Week 9717 Derwent Publications
 Ltd., London, GB; Class B04, AN 97-188310 XP002030695 &
 JP09048738 A (SNOW BRAND MILK PROD CO LTD), 18 February
 1997